Anaheim Clinical Trials (ACT)
Anaheim, California, 92801, United States
NCT Number: NCT06715683
This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Anaheim, California, 92801, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to Day 24
Time frame: Up to 28 Days Post-discontinuation of Study Intervention
Time frame: Up to Day 25
Time frame: Up to Day 25
Time frame: Up to Day 25
Bristol-Myers Squibb
Industry
An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of BMS-986278 To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details